AMP Capital Investors Ltd decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 70,405 shares of the company’s stock after selling 7,002 shares during the quarter. AMP Capital Investors Ltd owned 0.08% of IDEXX Laboratories worth $11,011,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Zions Bancorporation bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth approximately $162,000. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of IDEXX Laboratories by 1,000.0% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock worth $172,000 after purchasing an additional 1,000 shares during the last quarter. SignalPoint Asset Management LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $200,000. Ledyard National Bank lifted its holdings in shares of IDEXX Laboratories by 58.9% in the 4th quarter. Ledyard National Bank now owns 1,295 shares of the company’s stock worth $203,000 after purchasing an additional 480 shares during the last quarter. Finally, Unio Capital LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $203,000. 87.09% of the stock is currently owned by institutional investors and hedge funds.
In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 2,160 shares of IDEXX Laboratories stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $167.03, for a total transaction of $360,784.80. Following the sale, the chief executive officer now owns 1,077,112 shares of the company’s stock, valued at approximately $179,910,017.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $165.15, for a total value of $2,972,700.00. Following the sale, the chief executive officer now directly owns 1,077,112 shares in the company, valued at approximately $177,885,046.80. The disclosure for this sale can be found here. Insiders have sold a total of 91,736 shares of company stock worth $16,193,502 in the last ninety days. 2.77% of the stock is owned by company insiders.
Shares of IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $203.58 on Thursday. The company has a debt-to-equity ratio of -11.26, a quick ratio of 0.80 and a current ratio of 0.97. The firm has a market capitalization of $17,780.00, a price-to-earnings ratio of 62.07, a price-to-earnings-growth ratio of 2.51 and a beta of 0.58. IDEXX Laboratories, Inc. has a 12 month low of $146.09 and a 12 month high of $206.49.
IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, February 1st. The company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.04. The firm had revenue of $506.00 million for the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The firm’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.58 EPS. equities research analysts expect that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current fiscal year.
Several analysts recently issued reports on the company. BidaskClub raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 7th. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 price target on the stock in a report on Monday, February 5th. Bank of America raised their price target on IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. Piper Jaffray Companies raised their price target on IDEXX Laboratories to $211.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Finally, Canaccord Genuity reissued a “buy” rating and issued a $210.00 price target on shares of IDEXX Laboratories in a report on Monday, January 29th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $194.00.
TRADEMARK VIOLATION NOTICE: “AMP Capital Investors Ltd Decreases Stake in IDEXX Laboratories, Inc. (IDXX)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/03/15/amp-capital-investors-ltd-decreases-stake-in-idexx-laboratories-inc-idxx.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.